Biohaven looks to obesity to bounce back from run of clinical and regulatory failures

After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate for obesity.